CA2246487A1 - Dosage de l'adn pour prevoir le diabete auto-immun - Google Patents

Dosage de l'adn pour prevoir le diabete auto-immun Download PDF

Info

Publication number
CA2246487A1
CA2246487A1 CA 2246487 CA2246487A CA2246487A1 CA 2246487 A1 CA2246487 A1 CA 2246487A1 CA 2246487 CA2246487 CA 2246487 CA 2246487 A CA2246487 A CA 2246487A CA 2246487 A1 CA2246487 A1 CA 2246487A1
Authority
CA
Canada
Prior art keywords
alleles
class iii
ins
allele
class
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2246487
Other languages
English (en)
Inventor
Constantin Polychronakos
Rosemarie Grabs
Petros Vafiadis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Original Assignee
McGill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McGill University filed Critical McGill University
Priority to CA 2246487 priority Critical patent/CA2246487A1/fr
Publication of CA2246487A1 publication Critical patent/CA2246487A1/fr
Priority to US09/909,962 priority patent/US6534272B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA 2246487 1998-09-03 1998-09-03 Dosage de l'adn pour prevoir le diabete auto-immun Abandoned CA2246487A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA 2246487 CA2246487A1 (fr) 1998-09-03 1998-09-03 Dosage de l'adn pour prevoir le diabete auto-immun
US09/909,962 US6534272B2 (en) 1998-09-03 2001-07-23 DNA assay for the prediction of autoimmune diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2246487 CA2246487A1 (fr) 1998-09-03 1998-09-03 Dosage de l'adn pour prevoir le diabete auto-immun

Publications (1)

Publication Number Publication Date
CA2246487A1 true CA2246487A1 (fr) 2000-03-03

Family

ID=29409840

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2246487 Abandoned CA2246487A1 (fr) 1998-09-03 1998-09-03 Dosage de l'adn pour prevoir le diabete auto-immun

Country Status (1)

Country Link
CA (1) CA2246487A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012139A2 (fr) * 2001-07-31 2003-02-13 Pierre Bougneres Methodes d'evaluation du risque d'obesite reposant sur des variations alleliques dans la region flanquante 5' du gene de l'insuline

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012139A2 (fr) * 2001-07-31 2003-02-13 Pierre Bougneres Methodes d'evaluation du risque d'obesite reposant sur des variations alleliques dans la region flanquante 5' du gene de l'insuline
WO2003012139A3 (fr) * 2001-07-31 2003-09-18 Pierre Bougneres Methodes d'evaluation du risque d'obesite reposant sur des variations alleliques dans la region flanquante 5' du gene de l'insuline

Similar Documents

Publication Publication Date Title
EP1996728B1 (fr) Détection d'anomalies chromosomiques à l'aide de polymorphismes mononucléotidiques tandem
EP2118298B1 (fr) Tests a base d'acide nucléique destinés au typage rhd
US10081841B2 (en) Detecting fetal chromosomal abnormalities using tandem single nucleotide polymorphisms
US20090186340A1 (en) Gene Analysis
EP2821503B1 (fr) Procédé de détection de l'allèle hla-a*31:01
JP4073471B2 (ja) 塩基変異分析用プライマー
Hessner et al. Genotyping of KEL1 and KEL2 of the human Kell blood group system by the polymerase chain reaction with sequence‐specific primers
Navon et al. Prenatal diagnosis of Charcot‐Marie‐Tooth disease type 1A (CMT1A) using molecular genetic techniques
US6534272B2 (en) DNA assay for the prediction of autoimmune diabetes
US6303294B1 (en) Methods of detecting genetic deletions and mutations associated with Digeorge syndrome, Velocardiofacial syndrome, CHARGE association, conotruncal cardiac defect, and cleft palate and probes useful therefore
Camaschella et al. Allelic association of microsatellites of 6p in Italian hemochromatosis patients
Hessner et al. Prenatal genotyping of Jka and Jkb of the human Kidd blood group system by allele‐specific polymerase chain reaction
EP0787806B1 (fr) Polymorphismes de la séquence de la glycosyltransferase ABO
CA2246487A1 (fr) Dosage de l'adn pour prevoir le diabete auto-immun
WO2013052862A1 (fr) Marqueur génétique pour la prédiction du pronostic chez des patients infectés avec le virus de l'hépatite c
US20040091897A1 (en) Disease associated polymorphism in the ctla-4 locus
KR102063486B1 (ko) Rnf213 단일염기다형성과 한국인 모야모야병 발병 위험도의 연관성
Fodor et al. Molecular exclusion of haemoglobin SD disease by prenatal diagnosis
CN112940099B (zh) RhD-T163P突变体及其检测
Horiuchi et al. Polymerase chain reaction-based analysis using deaminated DNA of dodecamer expansions in CSTB, associated with Unverricht-Lundborg myoclonus epilepsy
WO2002066639A1 (fr) Gene sensible a l'anevrisme cerebral
Matsuo et al. Allele‐specific restriction analysis of human platelet antigen system 4
Ahmed An approach for the prevention of thalassaemia in Pakistan
EP2380992A1 (fr) Procédé de prédiction d'une réponse anticorps dans la thérapie à interférons chez les patients souffrant de sclérose en plaques
US20190100799A1 (en) Compositions and methods of detecting myelitis

Legal Events

Date Code Title Description
FZDE Dead